The deal with see Adaptimmune receive $150m upfront, another $150m over the next five years and then milestone payments potentially exceeding $3bn in aggregate sales, as well as royalties.
Unlike other leaders in next-generation cell therapies, the partners will use allogenic T-cells rather than immune cells taken from and returned to an individual’s body as with many CAR-T therapies including Kymriah (tisagenlecleucel).
